Segment information

9 Months Ended

Sep. 30, 2022

Segment information

Segment information

16. Segment information

The Company’s operations are comprised of two reportable segments:

● Diagnostics, which consists of TRUFORMA products, and

● Therapeutics, which consists of PulseVet and Assisi products

The Company’s Chief Operating Decision Maker (CODM) is its Chief Executive Officer who has ultimate responsibility for enterprise decisions.

Although our reportable segments provide similar products, each one is managed separately to better align with the Company’s customers and distribution / development partners. The CODM determines resource allocation for, and monitors performance of, the consolidated enterprise, the Diagnostics segment, and the Therapeutics segment together. The CODM relies on internal segment reporting that analyzes results on certain key performance indicators, namely, revenues and gross profit. Costs below gross profit are not allocated to the segments.

The following is a reconciliation of consolidated revenue, cost of revenue, and gross profit amongst our reportable segments:

	Diagnostics		Therapeutics		Consolidated
Net revenue	$	242	$	12,531	$	12,773
Cost of revenue		149		3,266		3,415
Gross profit (loss)	$	93	$	9,265	$	9,358